Fundraising Fox
Avitide
AcquiredLebanon, US · Founded 2012 · Delaware corporation · 8 known investors
Find your way into Avitide
Sign up to see every warm intro you have to Avitide
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Avitide team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Repligen provides bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows. It serves biopharma and CDMO teams developing and manufacturing modalities such as monoclonal antibodies, ADCs, mRNA, and cell and gene therapies.
Founders & leadership
Avitide was founded in 2012 by Tillman Gerngross and Errik Anderson.
Board
Investors · 8
How we know: OrbiMed's portfolio page · funding news · biospace.com · the VCSheet dataset · Not right? Tell us
How we know: SV Health Investors's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: board seat on SEC Form D · funding news · biospace.com · Not right? Tell us
How we know: biospace.com · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: funding news · biospace.com · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$39.5M disclosed across 6 rounds · 2014–2019
▶$10MraisedOct 2019 · 9 investors · BiotechnologyRule 506(b)
- Rishi GuptaDirector
- Ajay RoyanDirector
- Philip FerneauDirector
- Claudio NessiDirector
- Ian RatcliffeDirector
- Tillman GerngrossDirector
- Scott KennedyExecutive Officer
- Kevin IsettExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.2MraisedAug 2018 · 4 investors · PharmaceuticalsRule 506(b)
- Tillman GerngrossDirector
- Scott KennedyExecutive Officer
- Rishi GuptaDirector
- Ajay RoyanDirector
- Philip FerneauDirector
- Claudio NessiDirector
- Ian RatcliffeDirector
- Kevin IsettExecutive Officer, Director
- Offering amount
- $6.2M
- Amount sold
- $6.2M
- Proceeds to insiders
- $672K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedJan 2018 · 3 investors · PharmaceuticalsRule 506(b)
- Warren KettExecutive Officer
- Tillman GerngrossDirector
- Claudio NessiDirector
- Rishi GuptaDirector
- Scott KennedyExecutive Officer
- Ian RatcliffeDirector
- Colin GreensponDirector
- Philip FerneauDirector
- Kevin IsettExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $4M
- Proceeds to insiders
- $440K
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MraisedJun 2017 · 10 investors · PharmaceuticalsRule 506(b)
- Ian RatcliffeDirector
- Philip FerneauDirector
- Rishi GuptaDirector
- Colin GreensponDirector
- Scott KennedyExecutive Officer
- Michael RossDirector
- Warren KettExecutive Officer
- Tillman GerngrossDirector
- Kevin IsettExecutive Officer, Director
- Claudio NessiDirector
- Offering amount
- $12M
- Amount sold
- $12M
- Proceeds to insiders
- $682.5K
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$3.8MraisedAug 2015 · 11 investors · BiotechnologyRule 506(b)
- Kevin IsettExecutive Officer, Director
- Claudio NessiDirector
- Warren KettExecutive Officer
- Jon ShellerExecutive Officer
- Michael RossDirector
- Rishi GuptaDirector
- Philip FerneauDirector
- Tillman GerngrossDirector
- Offering amount
- $7.7M
- Amount sold
- $3.8M
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$3.4MraisedJun 2014 · 7 investors · BiotechnologyRule 506(b)
- Jonathan ShellerExecutive Officer
- Rishi GuptaDirector
- Michael RossDirector
- Errik AndersonDirector
- Philip FerneauDirector
- Warren KettExecutive Officer
- Kevin IssettExecutive Officer, Director
- Offering amount
- $3.4M
- Amount sold
- $3.4M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Avitide.
Frequently asked questions
- What does Avitide do?
- Repligen provides bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows. It serves biopharma and CDMO teams developing and manufacturing modalities such as monoclonal antibodies, ADCs, mRNA, and cell and gene therapies.
- Who founded Avitide?
- Avitide was founded by Tillman Gerngross, Errik Anderson in 2012.
- Who are Avitide's investors?
- Avitide's investors include OrbiMed, SV Health Investors, Borealis Ventures, Mithril Capital Management, Neomed Management, Polaris Partners, Sands Capital Ventures, SV Life Sciences.
- How much funding has Avitide raised?
- Avitide has disclosed $39.5M raised across 6 rounds.
- Where is Avitide headquartered?
- Avitide is headquartered in Lebanon, US.